
PRODUCT INFORMATION

Vebreltinib

Item No. 46227

CAS Registry No.:	1440964-89-5
Formal Name:	6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-[difluoro(6-fluoro-2-methyl-2H-indazol-5-yl)methyl]-1,2,4-triazolo[4,3-b]pyridazine
Synonyms:	APL 101, Beritinib, Bozitinib, CBI 3103, PLB 1001
MF:	$C_{20}H_{15}F_3N_8$
FW:	424.4
Purity:	≥98%
Supplied as:	A solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Vebreltinib is supplied as a solid. A stock solution may be made by dissolving the vebreltinib in the solvent of choice, which should be purged with an inert gas. Vebreltinib is soluble (≥10 mg/ml) in DMSO.

Description

Vebreltinib is a brain-penetrant inhibitor of c-Met.[1] It inhibits MET activity by 95% in an enzyme assay at 2 µM. Vebreltinib (30 µM) inhibits the phosphorylation of MET and STAT3 in primary human astrocytes expressing an exogenous PTPRZ1-MET (ZM) fusion or the MET exon 14 skipping alteration (*MET*ex14). It reduces tumor weight in a subcutaneous mouse xenograft model of glioma using U87MG cells expressing the E2-E2 ZM fusion variant. It increases survival in an orthotopic mouse xenograft model using the same cells. Vebreltinib also reduces the viability of MKN45 gastric cancer cells with MET amplification (IC_{50} = 12 nM) but not KATO III gastric cancer cells with low c-Met expression (IC_{50} = >1,000 nM).[2] Formulations containing vebreltinib have been used in the treatment of non-small cell lung cancer in patients with the *MET*ex14 alteration.

References

1. Hu, H., Mu, Q., Bao, Z., *et al.* Mutational landscape of secondary glioblastoma guides MET-targeted trial in brain tumor. *Cell* **175(6)**, 1665-1678 (2018).
2. Lin, H., Qu, L., Wei, H., *et al.* Characterization of Bozitinib as a potential therapeutic agent for MET-amplified gastric cancer. *Commun. Biol.* **8(1)**, 134 (2025).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent *via* email to your institution.

WARRANTY AND LIMITATION OF REMEDY
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 08/28/2026

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM